Gosebruch Henry O — SEC insider filings

SEC reporting owner CIK 1659625. 20 insider filings on record with FilingPulse; latest filed 2026-08-27.

Transaction summary — filings shown

Covers all 20 filings on record, filed 2020-10-02 to 2026-08-27. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
AbbVie Inc. (ABBV)EVP, Chief Strategy Officer10—15 legs · 272,920 sh · $39,590,85918
ACELYRIN, Inc. (SLRN)Director31 leg · 50,000 sh · $900,000—6
Neumora Therapeutics, Inc. (NMRA)President & CEO, Director21 leg · 15,000 sh · $189,370—2
Aptinyx Inc. (APTX)Director4——4
ANI PHARMACEUTICALS INC (ANIP)Director1——1

Insider filings — Gosebruch Henry O

FiledFormIssuerReported transactionsSource
2026-08-274ANI PHARMACEUTICALS INC (ANIP)Grant/award (A): 6,662 @ $0EDGAR
2025-05-234ACELYRIN, Inc. (SLRN)Disposition to issuer (D): 50,000 · Disposition to issuer (D): 92,158 (derivative) · Disposition to issuer (D): 155,450 (derivative)EDGAR
2024-06-114ACELYRIN, Inc. (SLRN)Grant/award (A): 92,158 (derivative) @ $0EDGAR
2024-02-164Neumora Therapeutics, Inc. (NMRA)Grant/award (A): 80,000 @ $0 · Grant/award (A): 160,000 (derivative) @ $0EDGAR
2023-09-194Neumora Therapeutics, Inc. (NMRA)Purchase (P): 15,000 @ $12.62EDGAR
2023-05-114ACELYRIN, Inc. (SLRN)Purchase (P): 50,000 @ $18 · Other (J): 155,450 (derivative) @ $0 · Other (J): 155,450 (derivative) @ $0EDGAR
2022-05-314Aptinyx Inc. (APTX)Grant/award (A): 40,000 (derivative) @ $0EDGAR
2022-05-204/AAbbVie Inc. (ABBV)Sale (S): 15,733 @ $146.81 · Sale (S): 5,167 @ $147.60 · Sale (S): 4,000 @ $148.71 · Sale (S): 100 @ $149.38EDGAR
2022-05-204/AAbbVie Inc. (ABBV)Option exercise (M): 83,960 @ $54.86 · Sale (S): 83,960 @ $155 · Option exercise (M): 83,960 (derivative) @ $54.86EDGAR
2022-05-184AbbVie Inc. (ABBV)Option exercise (M): 83,960 @ $54.86 · Sale (S): 83,960 @ $155 · Option exercise (M): 83,960 (derivative) @ $54.86EDGAR
2022-03-024AbbVie Inc. (ABBV)Sale (S): 15,733 @ $146.81 · Sale (S): 5,167 @ $147.60 · Sale (S): 4,000 @ $148.71 · Sale (S): 100 @ $149.38EDGAR
2022-03-014AbbVie Inc. (ABBV)Tax withholding (F): 30,156 @ $149.54 · Sale (S): 5,596 @ $147.54 · Sale (S): 8,303 @ $148.62 · Sale (S): 1,101 @ $149.14EDGAR
2022-02-224AbbVie Inc. (ABBV)Grant/award (A): 36,673 @ $0 · Grant/award (A): 7,972 @ $0 · Grant/award (A): 14,722 @ $0 · Grant/award (A): 8,701 @ $0 · Grant/award (A): 30,647 (derivative) @ $0EDGAR
2021-09-104AbbVie Inc. (ABBV)Gift (G): 30,000 @ $0 · Gift (G): 30,000 @ $0EDGAR
2021-06-014Aptinyx Inc. (APTX)Grant/award (A): 40,000 (derivative) @ $0EDGAR
2021-03-024AbbVie Inc. (ABBV)Tax withholding (F): 22,833 @ $107.74EDGAR
2021-02-224AbbVie Inc. (ABBV)Grant/award (A): 22,287 @ $0 · Grant/award (A): 6,555 @ $0 · Grant/award (A): 7,972 @ $0 · Grant/award (A): 14,724 @ $0 · Grant/award (A): 49,068 (derivative) @ $0EDGAR
2021-01-054Aptinyx Inc. (APTX)Grant/award (A): 5,339 (derivative) @ $2.22EDGAR
2020-11-244AbbVie Inc. (ABBV)Sale (S): 6,900 @ $98.83 · Sale (S): 33,100 @ $99.49EDGAR
2020-10-024Aptinyx Inc. (APTX)Grant/award (A): 5,490 (derivative) @ $2.16EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1659625 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs